Early PIVKA-II Response Associated with Treatment Efficacy and Survival Outcomes for Patients with Advanced Hepatocellular Carcinoma Receiving Immune Checkpoint Inhibitors and Targeted Therapy [PDF]
Journal of Hepatocellular CarcinomaZheng-Kang Fang,1,2 Yu-Ting Xiao,1 Xia Feng,1 Zhe-Jin Shi,1,3 Si-Yu Liu,4 Yang Yu,5 Li-Ming Jin,1 Dong-Sheng Huang,1 Cheng-Wu Zhang,1 Jun-Wei Liu,1 Lei Liang1 1Department of General Surgery, Cancer Center, Hepatobiliary & Pancreatic Surgery and ...
Fang ZK +10 more
doaj +5 more sources
PIVKA-II but not dp-ucMGP is associated with aortic calcification in chronic kidney disease [PDF]
BMC NephrologyBackground Patients with chronic kidney disease (CKD) are susceptible to vascular calcification and vitamin K deficiency. Matrix gla protein (MGP) is a potent inhibitor of calcification requiring vitamin K for activation.
Jakob Nyvad +10 more
doaj +5 more sources
PIVKA-II: A biomarker for diagnosing and monitoring patients with pancreatic adenocarcinoma.
PLoS ONE, 2021 BackgroundPancreatic adenocarcinoma (PDAC) is an incurable cancer without adequate tumor markers. Our previous study has showed a better diagnostic performance of Protein Induced by Vitamin K Absence II (PIVKA-II) compared to currently used PDAC ...
Sara Tartaglione +5 more
doaj +5 more sources
Epitope characterization of an anti-PIVKA-II antibody and evaluation of a fully automated chemiluminescent immunoassay for PIVKA-II [PDF]
Clinical Biochemistry, 2015 Protein induced by vitamin K absence or antagonist-II (PIVKA-II) has been used as a tumor marker to aid in the diagnosis of hepatocellular carcinoma (HCC). We developed an anti-PIVKA-II monoclonal antibody, 3C10, and a fully automated quantitative immunoassay for PIVKA-II on the ARCHITECT® i-systems.
Kinukawa, Hideki +2 more
exaly +4 more sources
Cancer Medicine, 2023 Background Prothrombin induced by vitamin K absence‐II (PIVKA‐II) and Alpha‐fetoprotein (AFP) have been widely used as diagnostic markers in hepatocellular carcinoma (HCC), but the prognostic values of the two serum markers and their clinical usefulness ...
Ling Lan, Hong Wu, Yunshi Cai
exaly +3 more sources
Differential Associations of PIVKA-II with Epithelial and Mesenchymal Features in HCC and PDAC. [PDF]
Int J Mol SciHepatocellular carcinoma (HCC) and pancreatic ductal adenocarcinoma (PDAC) are aggressive malignancies characterized by a poor prognosis and resistance to conventional therapies.
Farina A +5 more
europepmc +3 more sources
Biological variation of PIVKA-II in blood serum of healthy subjects measured by automated electrochemiluminescent assay [PDF]
Practical Laboratory MedicineBackground: Prothrombin/Protein Induced by Vitamin K Absence-II (PIVKA-II) is a candidate biomarker of hepatocellular cancer, recommended both for diagnostics and monitoring. The aim was to evaluate biological variation (BV) of serum PIVKA-II.
Antonín Jabor +5 more
doaj +3 more sources
Combined PIVKA II and Vimentin-Guided EMT Tracking in Pancreatic Adenocarcinoma Combined Biomarker-Guided EMT Tracking in PDAC. [PDF]
Cancers (Basel)Simple Summary Protein Induced by Vitamin K Absence (PIVKA II), also known as Des-γ-Carboxy prothrombin (DCP), is an established tumor marker for hepatocellular carcinoma (HCC) and a good diagnostic performance has also been demonstrated for Pancreatic ...
Farina A +6 more
europepmc +3 more sources
PANC-1 Cell Line as an Experimental Model for Characterizing PIVKA-II Production, Distribution, and Molecular Mechanisms Leading to Protein Release in PDAC [PDF]
International Journal of Molecular SciencesPancreatic ductal adenocarcinoma (PDAC) represents a highly aggressive malignancy with a lack of reliable diagnostic biomarkers. Protein induced by vitamin K absence (PIVKA-II) is a protein increased in various cancers (particularly in hepatocellular ...
Emanuela Anastasi +2 more
exaly +3 more sources
International Journal of Biological Markers, 2018 Background: Several studies have been conducted to evaluate the prognostic value of prothrombin induced by vitamin K absence-II (PIVKA-II) overexpression in hepatocellular carcinoma patients treated with curative ablation.
Zhi-hong Liu, Jinlin Hou, Xueru Yin
exaly +3 more sources